{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:20:48Z","timestamp":1761218448819,"version":"3.40.4"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Thymic carcinoma (TC) is a malignant mediastinal tumor, and there are no established treatments for pre-treated patients with advanced TC. Recently, lenvatinib was approved for such patients in Japan, ahead of other countries. Higher dose lenvatinib may be more efficacious than conventional treatments, although many patients experience grade 3 hypertension. Therefore, lenvatinib dose reduction remains controversial in terms of efficacy and tolerability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>Case 1 involves a 72-year-old woman who underwent complete resection of TC and was taking cilnidipine and azilsartan for hypertension. Six years later, multiple lung metastases were observed, and lenvatinib was started. Case 2 involves a 60-year-old man with TC, and was taking amlodipine for hypertension. A chest computed tomography showed progression in primary and metastatic lesions, and the patient started lenvatinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>In both patients, grade 3 hypertension was observed after the administration of lenvatinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>In Case 1, lenvatinib dose was reduced 3 times because lenvatinib was not interrupted despite grade 3 hypertension. In contrast, in Case 2, lenvatinib was interrupted when grade 3 hypertension occurred and was resumed after a decrease in blood pressure to baseline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>In Case 2, higher tumor regression may have been achieved because of the maintenance of a high dose of lenvatinib compared with that in Case 1.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Lenvatinib is a promising agent for advanced TC; however, hypertension should be addressed cautiously, especially at the outset of administration. Lenvatinib may have to be appropriately interrupted and resumed as soon as the blood pressure is controlled to maximize efficacy and minimize toxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028476","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T13:11:45Z","timestamp":1641561105000},"page":"e28476","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Management of severe hypertension due to lenvatinib in patients with advanced thymic carcinoma"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-6997","authenticated-orcid":false,"given":"Kinnosuke","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-9428","authenticated-orcid":false,"given":"Takayuki","family":"Shiroyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Kuge","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiro","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Suga","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoharu","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Iwahori","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Nagatomo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Yamadaoka, Suita City, Osaka, Japan"},{"name":"Department of Immunopathology, WPI, Immunology Frontier Research Center (iFReC), Osaka University, Yamadaoka, Suita City, Osaka, Japan"},{"name":"Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Yamadaoka, Suita City, Osaka, Japan"},{"name":"Center for Infectious Disease for Education and Research (CiDER), Osaka University, Yamadaoka, Suita City, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/ejcts\/ezv380","article-title":"Myasthenia gravis with thymic epithelial tumour: a retrospective analysis of a Japanese database","volume":"49","author":"Nakajima","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","article-title":"Systemic therapy in advanced thymic epithelial tumors: insights from the RYTHMIC prospective cohort","volume":"13","author":"Merveilleux du Vignaux","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (remora): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.10.002","article-title":"Impact of duration of dose interruption on the efficacy of lenvatinib in phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Tahara","year":"2019","journal-title":"Eur J Cancer"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1210\/jc.2015-3989","article-title":"Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer","volume":"101","author":"Robinson","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:11:25Z","timestamp":1746331885000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028476"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":7,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028476","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"2021-11-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}